INS and type 2 diabetes mellitus: In conclusion, in T2D patients with poor metabolic control, either insulin naïve or treated with BOT or MDI schemes, the introduction of IDegLira produces not only a significant improvement of metabolic control, but also a marked reduction in glycemic fluctuations, which are demonstrated to have a major impact on the occurrence of diabetes-related micro- and macroangiopathic comorbidities.